1 in 2 people develop cancer in their lifetime
17M new cases per year
10M death annually
62% cancer incidence rates increase by 2040
Patients diagnosed late have 5 - 10% reduced chance of survival
Analysis of circulating tumour DNA (ctDNA) released from cancer cells (a subset of cell-free DNA (cfDNA) released from healthy tissue), is emerging as a breakthrough clinical tool for cancer screening. ctDNA provides a direct measurement of cancer DNA and enables the 'liquid biopsy' application with the convenience of collecting blood samples as a less-invasive alternative to surgical tissue biopsies. 6 global pharma companies have confirmed that the liquid biopsy is crucial for monitoring disease and response to treatment. However, current diagnostic solutions rely on complex, expensive ($5k/test) and time-consuming (1-2 weeks) sequencing technologies (PCR and next generation sequencing), limiting their utility for rapid and cost-effective screening.
Nanovery is developing a revolutionary point-of-care diagnostics solution offering 10X cheaper (£500/test) and 100X faster (1hr) cancer detection and monitoring. The solution is based on pioneering DNA nanotechnology/DNA computing techniques to create nanorobots that can distinguish between ctDNA and cfDNA in blood; when ctDNA is detected, the nanorobot releases a fluorescent signal, thus giving a rapid response to a clinician.
The nanorobot is able to identify specific genetic cancer mutations, providing insight into type and stage of disease. Using complex Al techniques, Nanovery will be able to design new nanorobots as cancer mutates, enabling personalised diagnostics/care and improving the speed and cost effectiveness of clinical trials.
Cancer DNA is in blood.
The nanorobot is inserted into the blood sample.
Nanorobots distinguishes specific cancer mutation.
After 1 - 2 hours it lights up if it found a mutation.
Thanks to AI, Nanovery designs new nanorobots for new cancer mutations.
Nanovery's solution has the potential to revolutionise the way cancers are diagnosed, offering the fastest (1-2 hours vs 1-2 weeks) and cheapest ($500 vs $5000 per test) point-of-care diagnostic. The solution will enable earlier detection and monitoring of cancer to improve survivability and will support the increasing shift towards personalised medicine in the oncology therapeutic area as it will enable individualised treatment through companion diagnostic tests for real-time and rapid results.